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Abstract The oxidative modification of low density lipoprotein
(LDL) may play a significant role in atherogenesis. HOCl
generated by the myeloperoxidase/H2O2/Cl3 system of activated
neutrophils may be operative in vivo making LDL atherogenic.
Tyrosine has been found to be oxidized by HOCl to p-hydroxy-
phenylacetaldehyde (p-HA) capable of modifying phospholipid
amino groups in LDL. As an amphiphatic phenolic compound,
p-HA may have the potential to act as an antioxidant in the lipid
phase of LDL. The present results show that (a) tyrosine exerts a
protective effect on LDL modification by HOCl, (b) p-HA could
act as antioxidant associated with the lipoprotein preventing cell-
and transition metal ion-mediated LDL oxidation and (c) p-HA
was able to scavenge free radicals. ß 2001 Federation of Euro-
pean Biochemical Societies. Published by Elsevier Science B.V.
All rights reserved.
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1. Introduction
The oxidative modi¢cation of low density lipoprotein
(LDL) may play an important role in the early events of
atherogenesis [1^4]. The pathophysiological relevant path-
way(s) of atherogenic LDL alterations, however, have not
been elucidated at present. There is some evidence that the
myeloperoxidase/hydrogen peroxide/chloride system (MPO/
H2O2/Cl3) of activated neutrophils may be operative in vivo
modifying LDL [5^9]. However, a pivotal role of MPO in
neutrophil-induced oxidation of LDL has been questioned
by Noguchi et al. using MPO knockout mice [10]. In addition,
the MPO/H2O2/NO32 system by producing reactive nitrogen
species [11] has been identi¢ed as a further candidate for in
vivo LDL atherogenic modi¢cation by MPO [12,13]. The re-
action product HOCl of the MPO/H2O2/Cl3 system has been
shown to induce the formation of protein chloramines in LDL
and secondary derived radicals initiate lipid oxidation [14^16].
Actually, HOCl-modi¢ed proteins have been detected in athe-
rosclerotic lesions [9,17]. Free amino acids react with HOCl
by forming chloramines which decompose by deamination
and decarboxylation to the respective aldehyde. These alde-
hydes are capable of modifying protein amino groups via the
formation of Schi¡ bases [18^25]. Recently, Heller et al. [26]
reported that tyrosine in presence of reagent HOCl, MPO/
H2O2/Cl3 or activated neutrophils which employ the MPO
system was converted to the lipid-soluble aldehyde, p-hy-
droxyphenylacetaldehyde (p-HA). p-HA was found to modify
phospholipid amino groups (phosphoethanolamine) in LDL
[26]. Such p-HA-modi¢ed LDL particles were actually isolated
from atherosclerotic plaques indicating that this reaction may
also occur in vivo [26]. However, the pathophysiological role
of this particular LDL modi¢cation is uncertain at present.
One may assume that p-HA, due to its phenolic structure and
amphiphatic nature, may have the property to act as an anti-
oxidant in the lipid phase of LDL. Therefore, in the present
paper we have evaluated (a) the in£uence of tyrosine on
HOCl-initiated LDL modi¢cation and (b) the sensitivity of
p-HA pretreated LDL to lipid oxidating processes. The
present results show that pretreatment of LDL with HOCl/
tyrosine by generating p-HA protected LDL from further oxi-
dative attacks mediated by endothelial cells or transition met-
al ions.
2. Materials and methods
Sodium hypochlorite (NaOCl) solution was from Aldrich Chemical
Company, Inc. Tyrosine (sodium salt), phenylalanine, tyrosine [ring-
3,5-3H] speci¢c activity 45.5 Ci/mmol, 2,2-diphenyl-1-picrylhydrazyl
(DPPH) and galvinoxyl were purchased from Sigma-Aldrich Chemical
Corp. All other chemicals used were of analytical grade.
2.1. LDL isolation
LDL preparations were isolated by ultracentrifugation as reported
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previously [27]. The ¢nal preparations were dialyzed against 150
mmol/l NaCl containing 0.1 mmol/l EDTA and ¢lter sterilized. Pro-
tein was estimated by a commercial test kit (Bio-Rad Laboratories)
using bovine serum albumin as a standard. All LDL concentrations
are given as mg protein/ml.
2.2. Endothelial cell culture
Endothelial cells (HUVECs) were isolated from human umbilical
veins and maintained in culture as reported previously [28]. For ex-
periments cells were passaged into 35 mm culture dishes. All incuba-
tions were done in RPMI-1640 medium.
2.3. LDL oxidation
2.3.1. HOCl-mediated LDL oxidation. Prior to LDL oxidation,
the lipoprotein was equilibrated in 0.1 mol/l phosphate bu¡er pH
7.4 containing 100 Wmol/l DTPA using Sephadex G-25 chromatogra-
phy (PD-10 columns, Pharmacia). LDL (2 mg/ml) was incubated with
reagent HOCl up to 1 mmol/l at 37‡C for 18 h. Stock HOCl concen-
tration was estimated spectrophotometrically in 0.01 mol/l NaOH us-
ing O292 as 350 M31 cm31 [15]. For LDL treatment, stock HOCl was
diluted with phosphate bu¡er. At the end of incubations LDL samples
were applied to small Sephadex columns (Nick column, Pharmacia)
equilibrated in PBS pH 7.4 to separate low molecular weight com-
pounds prior to analytical procedures or further treatment.
2.3.2. Cell-mediated LDL oxidation. When cell-mediated LDL ox-
idation was performed, HUVEC con£uent monolayers were washed
with RPMI-1640 medium and subsequently incubated with the respec-
tive LDL preparation (100 Wg/ml) in RPMI-1640 for 24 h. Results
were obtained with four di¡erent HUVEC preparations.
2.3.3. Transition metal ion-mediated LDL oxidation. LDL prepa-
rations obtained after gel chromatography on Nick columns (see
above) were diluted to 200 Wg/ml protein and lipid oxidation was
initiated by addition of Cu2 (10 Wmol/l). Samples were incubated
at 37‡C.
2.4. Estimation of LDL oxidation
2.4.1. Lipid hydroperoxides. Total lipid hydroperoxides were mea-
sured with the CHOD iodide color reagent (O365 = 1.73U104 M31
cm31 ; E. Merck) as described by El-Saadani et al. [29] and validated
for LDL by Gebicki et al. [30] under the conditions of Wallin and
Camejo [31]. To avoid interference of any remaining chloramines with
the CHOD reagent, methionine (2 mmol/l) was added at the end of
the treatment and the samples were further incubated for 60 min at
37‡C. Subsequently 0.4 ml sample was mixed with 0.4 ml CHOD
iodide reagent and after incubation for 60 min at 37‡C the absorbance
was estimated at A365 nm. All values are given as Wmol/l in the assay.
2.4.2. Conjugated dienes. Conjugated diene formation was moni-
tored as the increase in absorbance at A234 nm [32] using a Hitachi U-
2000 spectrophotometer. ‘Lag time’ of LDL oxidation was calculated
as de¢ned by [32].
2.4.3. Thiobarbituric acid assay. LDL oxidation products in cell
culture supernatants were assayed as TBARS as described [27].
2.5. Lipid electrophoresis
Aliquots (10 Wl) of treated or untreated LDL were applied to aga-
rose gels (1% in veronal bu¡er), run for 90 min and lipoproteins were
detected according to the supplier of the analytical system (Lipido-
phor All In, Immuno-Baxter AG). Measurement of relative electro-
phoretic mobility (REM) was taken as an indicator of LDL oxidation
[33], setting the electrophoretic mobility of native (untreated) LDL
arbitrarily as 1.
2.6. Preparation of p-hydroxyphenylacetaldehyde
p-HA was prepared by mixing equimolar amounts of tyrosine and
HOCl in phosphate bu¡er at 4‡C and subsequently the mixture was
incubated for 60 min at 37‡C following the protocol of [24]. Samples
were supplemented with LDL (2 mg/ml) and further incubated for 2 h
at 37‡C. Low molecular weight compounds were separated by gel
chromatography as described above.
2.7. Binding of p-HA to LDL
p-HA (500 Wmol/l) was prepared as described above using
[3H]tyrosine as a tracer (6.25 WCi/ml). Samples were supplemented
with LDL (2 mg/ml) and further incubated for 2 h at 37‡C. Low
molecular weight compounds were separated by gel chromatography
and bound p-HA was estimated by liquid scintillation counting. Par-
allel incubations were run as background controls using radioactive
tyrosine only (no HOCl added).
2.8. Free radical scavenging
Radical scavenging ability of p-HA was estimated using the stable
free radical compounds DPPH and galvinoxyl [34^36]. To methanolic
solutions of DPPH (50 Wmol/l) or galvinoxyl (10 Wmol/l) p-HA was
added (50 Wmol/l) and the absorption was read at 517 nm (DPPH) or
429 nm (galvinoxyl), respectively. 2,6-di-tert-butyl-4-methylphenol
(BHT, 50 Wmol/l) was run as a positive control. The decrease in
absorption was taken as an indicator of radical scavenging ability
[34^36].
3. Results and discussion
HOCl, the product of the activated myeloperoxidase system
(MPO/H2O2/Cl3) is a potent bio-reagent [37] known to mod-
ify LDL [14^16,38]. HOCl (1 mmol/l) treatment of LDL re-
sulted in modi¢cation of the apoprotein as indicated by in-
creased REM of the lipoprotein (Fig. 1). When tyrosine was
present in the incubations (molar ratio 1:1) the amino acid
suppressed REM from 1.88 (HOCl) to 1.55 (see Fig. 1) pre-
sumably by scavenging HOCl. Estimation of lipid hydroper-
oxides revealed that tyrosine (0.250^1 mmol/l) e¡ectively in-
hibited lipid oxidation in LDL initiated by HOCl (Fig. 1). It
should be noted that the concentration of 1 mM HOCl which
was used in this experiment is about 10 times higher than the
concentration of HOCl generated by 1U106 neutrophils/ml.
Tyrosine in presence of reagent HOCl (or MPO/H2O2/Cl3) is
converted in quantitative yield (mol/mol) to the phenolic al-
dehyde, p-HA [24^26]. In general, phenolics have antioxida-
tive properties. To evaluate the e¡ect of p-HA on LDL oxi-
dation, LDL was preincubated for 18 h at 37‡C with tyrosine/
HOCl (500 Wmol/l each) to generate p-HA and after gel sep-
aration LDL samples were subjected to cell-mediated oxida-
tion using HUVECs as an LDL oxidating system [39]. Lipid
oxidation products (TBARS) were estimated in culture media
of HUVECs treated with the respective LDL preparation. As
seen in Fig. 2, LDL pretreated with HOCl/tyrosine was less
prone to lipid oxidation compared to native LDL. Under
these conditions, about 50% lower TBARS formation was
observed in tyrosine/HOCl pretreated LDL. This is obviously
due to p-HA associated with the lipoprotein as all LDL prep-
Fig. 1. In£uence of tyrosine on protein and lipid modi¢cation in
LDL initiated by HOCl. LDL (2 mg/ml) was incubated in 0.1 mol/l
phosphate bu¡er, pH 7.4, 100 Wmol/l DTPA in the absence or pres-
ence of 1 mmol/l HOCl and tyrosine (0^1 mmol/l) for 18 h at 37‡C.
At the end of incubation, REM (E) and lipid hydroperoxides (R)
(after gel chromatography) were estimated as given in Section 2.
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arations were subjected to gel chromatography to separate
low molecular weight compounds prior to cell-mediated oxi-
dation. Using [3H]tyrosine/HOCl reaction mixtures to gener-
ate radioactively labelled p-HA about 6.85 þ 0.82 nmol of
p-HA/mg of protein (n = 3) were found to be associated with
the lipoprotein fraction after 18 h incubation at 37‡C. LDL
pretreatment with phenylalanine/HOCl (500 Wmol/l each) had
no antioxidative e¡ect in this system. This is in accordance to
the chemical nature of the compound formed by phenyl-
alanine/HOCl, namely phenylacetaldehyde [22] ^ a lipophilic
but non-phenolic compound unable to act as an antioxidant.
Tyrosine (no HOCl present) pretreatment of LDL had also no
protective e¡ect on subsequent cell-mediated LDL oxidation
(Fig. 2). The inset in Fig. 2 shows the concentration-depen-
dent e¡ect of tyrosine/HOCl mixtures (125^500 Wmol/l each)
on LDL oxidation by HUVECs. The maximal antioxidant
e¡ect on cell-mediated LDL oxidation was observed at 500
Wmol/l tyrosine and HOCl (molar ratio 1:1). The (relative)
potential of an antioxidant can be estimated by the kinetic
assay of conjugated diene formation in LDL [32]. Native,
HOCl or tyrosine/HOCl (generating p-HA) pretreated (18 h
at 37‡C) LDL was therefore subjected to copper ion-mediated
lipid oxidation and conjugated dienes were monitored. As
depicted in Fig. 3, tyrosine/HOCl pretreated LDL showed a
longer resistance to Cu2 (10 Wmol/l)-initiated LDL oxidation
compared to native LDL. This was indicated by a prolonged
lag phase of lipid oxidation (24 min versus 33 min). The inset
in Fig. 3 shows the e¡ect of 2 mmol/l p-HA on Cu2-initiated
lipid oxidation in LDL incubated for 2 h with already formed
p-HA (see Section 2) using another LDL preparation. This
‘short-time’ treatment e¡ectively protected LDL from lipid
oxidation, too. As described above, p-HA suppressed the ox-
idation of LDL by endothelial cells as well as transition metal
ions. It has been shown that potent antioxidants react with
Fig. 2. LDL oxidation by human endothelial cells. LDL (2 mg/ml)
in 0.1 mol/l phosphate bu¡er, pH 7.4, 100 Wmol/l DTPA was pre-
treated with HOCl (500 Wmol/l), tyrosine (500 Wmol/l), HOCl/tyro-
sine (both 500 Wmol/l) or HOCl/phenylalanine (both 500 Wmol/l) for
18 h at 37‡C. At the end of incubation samples were subjected to
gel chromatography (see Section 2) and the respective LDL prepara-
tion was added to HUVEC cultures (100 Wg/ml medium) and incu-
bated for 24 h. TBARS were estimated in the cell culture superna-
tants. Untreated LDL processed as described above served as
control. Inset: Concentration-dependent e¡ect of HOCl/tyrosine/
LDL pretreatment on cell-mediated LDL oxidation. LDL (2 mg/ml)
in 0.1 mol/l phosphate bu¡er, pH 7.4, 100 Wmol/l DTPA was pre-
treated with HOCl (125, 250, 500 Wmol/l)/tyrosine (125, 250, 500
Wmol/l) for 18 h at 37‡C and processed as described above.
Fig. 3. In£uence of tyrosine/HOCl pretreatment on LDL oxidizabil-
ity by transition metal ions. LDL (2 mg/ml) in 0.1 mol/l phosphate
bu¡er, pH 7.4, 100 Wmol/l DTPA was treated with HOCl/tyrosine
(500 Wmol/l each) for 18 h at 37‡C. After gel chromatography, LDL
samples were diluted to 0.2 mg/ml and lipid oxidation was initiated
by the addition of Cu2 (10 Wmol/l). Conjugated diene formation
was monitored as the increase in absorbance at A234 nm and lipid ox-
idation lag phase was calculated according to [31]. Untreated LDL
processed as described above served as control. Untreated LDL (a),
tyrosine/HOCl pretreatment (F). Inset: In£uence of reagent p-HA
treated LDL on oxidizability by Cu2. Reagent p-HA was prepared
as given in Section 2. LDL (2 mg/ml) was treated with 2 mmol/l)
p-HA for 2 h at 37‡C. After separation of low molecular weight
compounds, lipid oxidation was initiated by 10 Wmol/l Cu2 and
conjugated dienes monitored. Untreated LDL (a), reagent p-HA
pretreatment (F).
Fig. 4. Radical scavenging ability of p-HA. Reagent p-HA (50
Wmol/l) was added to a methanolic solution of DPPH radical (50
Wmol/l) or galvinoxyl radical (10 Wmol/l) and the decay in absorp-
tion was monitored for DPPH at 517 nm and galvinoxyl at 429 nm,
respectively. BHT (50 Wmol/l) was run as a positive control. No ad-
dition (O), p-HA (E), BHT (a).
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stable free radicals such as DPPH (N-centered radical) and
galvinoxyl (O-centered radical) [34^36]. Thus, the reactivity
of p-HA as a hydrogen donor was estimated by following a
decay of visible absorption of DPPH and galvinoxyl using
BHT as a positive control. The results show that p-HA reacts
with both radical species (Fig. 4) further indicating its poten-
tial antioxidant properties.
The present results show that free tyrosine has a protective
e¡ect on LDL modi¢cation by HOCl and that p-HA, the
reaction product of tyrosine and HOCl, could act as an anti-
oxidant associated with the lipoprotein in£uencing its altera-
tions induced by endothelial cells or transition metal ions. On
the other hand beside its bare antioxidant ability, p-HA may
bind to regions in the LDL molecule blocking copper binding
sites in the lipoprotein [40^43], thus resulting in lower oxidiz-
ability of LDL by transition metal ions. In this respect it
should be emphasized that a role ^ if any ^ of metal ion-
initiated LDL oxidation in atherogenic transformation of
LDL is not clear at present and is still a matter of debate
[7,44]. Thus one may assume that in vivo multiple modi¢ca-
tions may take place in parallel [7,45]. Although the described
antioxidant e¡ect of p-HA may be of bene¢t regarding the
pivotal role of LDL oxidation in atherogenesis [1], the impact
of p-HA-modi¢ed lipoproteins [46] in the pathophysiological
process of atherosclerosis must be kept in mind.
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